CompletedPhase 3

Nitric Oxide During Bypass for Arterial Switch Operation

Australia, Canada, Indonesia300 participantsStarted 2018-07-11

Plain-language summary

This trial will test if adding nitric oxide (NO) gas to the cardiopulmonary bypass (CPB) circuit in infants undergoing an arterial switch operation (ASO) for Transposition of the Great Arteries (TGA) changes the incidence of major postoperative adverse events (AEs). Major postoperative AEs include cardiac arrest, emergency chest opening, use of ECMO (machine that acts as an artificial heart and lung during surgery), and death. Participants will be randomised to receive oxygen plus nitric oxide (intervention arm) or oxygen without nitric oxide (control arm) during CPB.

Who can participate

Age range0 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria; Each participant must meet all of the following criteria to be enrolled in this study: * Infant aged greater than or equal to 36 weeks gestation * Infants less than 2 years * Diagnosed with TGA and requiring Arterial Switch Operation * Consent of parents/guardian. Exclusion criteria Potential participants will be excluded if they meet any of the following criteria: * They have multiple major congenital anomalies (anomalies which affect the infant's life expectancy or health status) * They have multiple other cardiac abnormalities (with the exception of ASD, VSD or PDA) * They weigh less than 2.2kgs. * Prior surgical exposure to cardio-pulmonary bypass

What they're measuring

Major adverse events

Timeframe: 28 days post intervention

Trial details

NCT IDNCT03661385

SponsorMurdoch Childrens Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-23

View on ClinicalTrials.gov More Low Cardiac Output Syndrome trials